Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.

摘要: ABSTRACTIntroduction: The introduction of novel agents has significantly improved multiple myeloma (MM) patient outcome during the last two decades. MM received most drug approvals for any one malignancy this time period, both in United States as well Europe.Areas covered: Proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies are prototype classes, which target specific cell functions, tumor supportive bone marrow microenvironment, represent current cornerstones therapy. Importantly, unprecedented extent frequency durable responses, relapsed/refractory (RRMM), particular, is predominantly based on combinatorial use these with conventional chemotherapeutics or representatives other classes. This article will summarize past landmark discoveries that led to dramatic progress today’s clinical practice. Moreover, developing strategies be discussed like...